Cited by

• Exploring Rosiglitazone's Potential to Treat Alzheimer's Disease through the Modulation of Brain-Derived Neurotrophic Factor.

  Nelson ML, Pfeifer JA, Hickey JP, Collins AE, Kalisch BE. Nelson ML, et al. Biology (Basel). 2023 Jul 24;12(7):1042. doi: 10.3390/biology12071042. Biology (Basel). 2023. PMID: 37508471 Free PMC article. Review.
• A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Effects of Biguanides (Metformin) and Thiazolidinediones on Glucose Tolerance and Insulin Sensitivity in Patients With Type II Diabetes Mellitus.

  Zaki HA, Iftikhar H, Shallik NA, Shaban E, Al-Marri NDR, Bashir I, Elhadad A, Zoghlami F, Abdalrubb A. Zaki HA, et al. Cureus. 2023 May 24;15(5):e39445. doi: 10.7759/cureus.39445. eCollection 2023 May. Cureus. 2023. PMID: 37362539 Free PMC article. Review.
• The forgotten type 2 diabetes mellitus medicine: rosiglitazone.

  Xu B, Xing A, Li S. Xu B, et al. Diabetol Int. 2021 Jun 29;13(1):49-65. doi: 10.1007/s13340-021-00519-0. eCollection 2022 Jan. Diabetol Int. 2021. PMID: 35059243 Free PMC article. Review.
• Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.

  Severino P, D'Amato A, Prosperi S, Costi B, Angotti D, Birtolo LI, Chimenti C, Lavalle C, Maestrini V, Mancone M, Fedele F. Severino P, et al. Heart Fail Rev. 2023 May;28(3):709-721. doi: 10.1007/s10741-021-10170-1. Epub 2021 Oct 16. Heart Fail Rev. 2023. PMID: 34654997 Free PMC article. Review.
• The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.

  Leonard CE, Brensinger CM, Dawwas GK, Deo R, Bilker WB, Soprano SE, Dhopeshwarkar N, Flory JH, Bloomgarden ZT, Gagne JJ, Aquilante CL, Kimmel SE, Hennessy S. Leonard CE, et al. Cardiovasc Diabetol. 2020 Feb 25;19(1):25. doi: 10.1186/s12933-020-00999-5. Cardiovasc Diabetol. 2020. PMID: 32098624 Free PMC article.